Kornimate/medical-research-clean huggingface dataset:
anatomical-clinical base of adenocarcinoma pancreatic

Conditions: Adenocarcinoma; Carcinoma; Neoplasms

Summary: bacap-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. the aim is to enrich the previous propective collection bacap in order to support future research projects.

pancreatic cancer represents the fourth cause of death by cancer in western countries. in over 90% of cases, it is due to an adenocarcinoma. the only curative treatment for pancreatic cancer remains the surgical exeresis. this one can only be suggested as a curative treatment in only 10 to 15% of cases. besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice. the research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. it is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy). the present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection bacap in order to support support future research projects on: * the development of new diagnostic tools, * understanding the development of tumors of the pancreas * the development of new therapeutic targets * understanding the response to chemotherapy...

Eligibility criteria:
inclusion criteria: * patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or * patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or * patient with pancreatic adenocarcinoma proven histologically and/or cytologically exclusion criteria: * patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma * pregnant or breastfeeding patient

Keywords: adenocarcinoma fine-needle aspiration endoscopic ultrasonography epidemiology biobank dna tumors
evaluation of enhanced syphilis screening among hiv-positive men

Conditions: Syphilis

Summary: this study aims to enhance syphilis testing among hiv-positive men who have sex with men (msm), so that more men will undergo testing, they will test more often, and more cases will be treated early. the intervention will combine syphilis tests with the standard hiv blood tests that are routinely done every 3-6 months for persons in care at hospital-based hiv clinics in toronto and ottawa, canada.

a clinic-based intervention to incorporate syphilis testing with routine hiv bloodwork among hiv-positive men who have sex with men (msm) attending 4 hospital-based hiv clinics in toronto and ottawa will be conducted. the objectives are to determine to what degree the intervention: (1) increases the detection rate of untreated syphilis; (2) increases the proportion of men who undergo syphilis testing at least annually (increased screening coverage); (3) reduces the interval between syphilis tests (increased screening frequency); and (4) reaches men at highest risk according to sexual behaviours. the main hypotheses are that the intervention will increase screening coverage to a minimum of 85% of men undergoing syphilis testing annually, increase screening frequency to a median of 3 tests per person per year, and increase the case detection rate by 75% or more. the design of this study is a cluster-randomized controlled trial with stepped wedge design that will gradually introduce the intervention across clinics. this pragmatic approach incorporates a concurrent comparison group, allows for assessment of time trends, will be well-powered, and will generate more generalizable results due to its inclusion of multiple clinics. the intervention will be operationalized as standing orders for syphilis serology when there is an order for hiv viral load and/or cd4 cell count. data sources include (1) syphilis tests submitted to the public health ontario laboratory; (2) a standardized clinical worksheet and medical chart review to validate diagnoses for screen test positives; and (3) data collected from a subset of patients via their participation in the ongoing ontario hiv treatment network (ohtn) cohort study. the latter follows adults in hiv care and collects data using chart reviews and annual face-to-face interviews including measures of sexual behaviour.

Eligibility criteria:
inclusion criteria: * male hiv patients * must be attending at least one of the four participating hospital-based hiv outpatient clinics exclusion criteria: * women
alzheimer's prevention registry: a program to accelerate enrollment into studies

Conditions: Alzheimer's Disease; Dementia

Summary: the alzheimer's prevention registry (www.endalznow.org) will collect contact and demographic information on individuals. the objective is to provide information the latest news and advances in alzheimer's prevention research, and to inform enrollees about research studies in their community. enrolled individuals will receive regular email communications. as research studies become available, individuals will be notified via email with information as to how proceed should they be interested. registry enrollees are under no obligation to participate in a research study. study opportunities may include surveys, healthy lifestyle interventions (e.g., diet, exercise), memory \& thinking tests, brain scans, and investigational drug trials. to join the registry, please visit www.endalznow.org


Eligibility criteria:
inclusion criteria: * must be able to accept the alzheimer's prevention registry website terms and conditions exclusion criteria: * none

Keywords: alzheimer's prevention
transcutaneous auricular vagus nerve stimulation in dry eye disease

Conditions: Dry Eye Disease

Summary: objective: to evaluate the effect of transcutaneous auricular vagus nerve stimulation (tavns) for the patients with dry eye disease with meibomian gland dysfunction. methods: we enrolled 256 patients at beijing tongren hospital. patients completed questionnaires at baseline, 1 month, 3 months, and 6 months.osdi score, tbut, schirmer i, tcfs, mgd score, and psychological status to evaluate the therapeutic effects. a difference of p \< 0.05 was considered statistically significant.


Eligibility criteria:
inclusion criteria: 1. age \>=18 and age \<=75. 2. clinical diagnosis of dry eye disease. exclusion criteria: 1. history of depression, tumors, thyroid disease, diabetes, cardiac diseases. 2. history of phthalmology surgery. 3. pregnant or lactating women.

Keywords: tavns dry eye rct
effects of prone position after major abdominal surgery

Conditions: Surgery; Complications, Postoperative; Lung Infection

Summary: evaluation of postoperative prone position after major abdominal surgery. a randomized clinical trial of 100+100 patients and further add a voice/speech/singing protocol.

evaluation of postoperative prone position after major abdominal surgery. a randomized clinical trial of 100+100 patients and further add a voice/speech/singing protocol. the patients will be randomized to the standard eras-protocol, enhanced recovery after surgery with or without adding periods of prone position after surgery. they will be followed by protocol both as a momentum effect (experimental study) on pod 2-5 and also pod 7. the aim is evaluation of prone position in order to improve the ventilation and hopefully diminish the risk of for example pneumonia and thromboembolism. inclusion criteria patients referred to the department of surgery for major abdominal surgery of the esophagus, gastric- or pancreas surgery aim to cure. exclusion criteria patients unable to understand swedish in writing or speaking, preoperatively unable to perform a prone position. the participation is voluntary and demands an inform consent from the patient operated upon. the primary outcome is oxygen saturation and lung complications after surgery. the secondary outcome is measurement of lung volumes, patient experience (7th graded lickert scale), days of hospital care, 30 days complications etc. further investigations are perioperative properties as bmi, other forms of surgery, etc., and continues measurement of blood pressure, respiration frequency, heartrate, tubes and drainages, postoperative analgesic, blood samples with signs of bleeding, inflammation, infection.

Eligibility criteria:
patients eligable for abdominal surgery aim to cure with: inclusion criteria: - malignancy of the esophagus, gastric- or pancreas exclusion criteria: -.not able to understand swedish in writing or speaking - preoperatively unable to perform a prone position

Keywords: complications postoperative lungcomplications abdominal surgery prone position
sleep apnea and fetal growth restriction

Conditions: Obstructive Sleep Apnea; Fetal Growth Restriction; Pregnancy Related

Summary: this study aims to evaluate the association between obstructive sleep apnea (osa) and fetal growth restriction (fgr) and to assess the role of auto-titrated positive airway pressure (apap) as antenatal therapy in these patients. pregnant patients with diagnosed fgr will be screened for osa first by screening questionnaire and then by home sleep monitor. of those patients diagnosed with osa, half will be assigned to use apap each night when sleeping and half will not (standard care).

fetal growth restriction (fgr) affects 5-10% of pregnancies and is one of the leading causes of perinatal morbidity and mortality. obstructive sleep apnea (osa) is a common disorder in which a person's breathing pauses or becomes shallow during sleep. these periods of low oxygen lead stress and inflammation which that may be harmful to both the mother and her fetus. osa in pregnancy has been associated with poor maternal-fetal outcomes, including low birth weight, preterm delivery, fgr, gestational hypertension/preeclampsia, gestational diabetes and higher rates of neonatal icu admission. auto-titrated positive airway pressure (apap) is a machine that gently delivers pressurized air via a mask to keep a patient's airways free of obstruction during sleep. it is currently unclear whether treatment of osa during pregnancy in women with known fgr can improve fetal and neonatal outcomes.

Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 50 * fetal growth restriction (defined as fetal weight \ 15th percentile on any ultrasounds prior to enrollment) * lower limit of gestational age at enrollment 22+0 weeks. * upper limit of gestational age at enrollment: adequate time to complete stages 1 and 2 and if appropriate to be randomized and receive intervention by no later than 32+0 weeks. * the absence of 2 minor or 1 major markers of aneuploidy. exclusion criteria: * other known cause of fetal growth restriction (including congenital anomalies, intrauterine infection, or multiple gestation) * reversed end-diastolic flow in the umbilical artery * preexisting diagnosis of osa being treated with apap * chronic pulmonary disease (cystic fibrosis, moderate persistent asthma) * hemoglobinopathies (sickle cell anemia, thalassemia) * maternal craniofacial anomalies * premature rupture of membranes

Keywords: apap osa fgr
analgesic strategies in newborns receiving prostaglandin therapy

Conditions: Pain

Summary: this is a randomised trial comparing the efficacy of 3 different analgesic strategies in newborns on prostaglandin for ductus dependent congenital heart disease.


Eligibility criteria:
inclusion criteria: * full-term newborn * under one month of age * with ductus dependent congenital heart disease requiring prostaglandin infusion and elevated pain score exclusion criteria: * contraindication to either morphine, acetaminophen, or nalbuphine * other painful condition * poor neurological condition * cardiac instability requiring urgent surgery

Keywords: prostaglandin analgesia congenital heart defect induced
low pulse amplitude focal ect (lap study)

Conditions: Depression

Summary: this protocol proposes a pilot randomized clinical trial to examine whether low pulse amplitude focal ect (lap) has a more favorable cognitive profile compared to conventional unilateral ect and that it has similar effects as traditional ect in reducing suicidality. the study will enroll 10 patients recruited from the medical college of georgia (at georgia regents university/augusta university, gru/au) as the only site of the study. eligible participants will be randomly assigned (1:1 ratio) to receive a course of either rul lap ect, or conventional rul ect.

lower amplitude ect (lap) has been shown to induce seizures of adequate duration in a single titration session. this current study is hypothesized to increase stimulation focality, thus hypothetically minimizing cognitive side effects. the central hypothesis is that lap has significantly less cognitive adverse effects compared to conventional right unilateral (rul) ect. the study will enroll 10 patients recruited from medical college of georgia. patients referred to ect service in the medical college of georgia usually occurs from clinical services and private physicians and the study will recruit patients who are clinically indicated to do ect. eligible participants will be randomly assigned (1:1 ratio) to receive a course of either rul lap ect, or conventional rul ect.

Eligibility criteria:
inclusion criteria: * patients in whom ect therapy is clinically indicated * males or females patients over 20 years of age * current dsm-iv criteria for major depressive episode * montgomery-asberg depression rating scale (madrs) greater than or equal to 20 * use of effective method of birth control for women of child-bearing capacity * patient is medically stable * no anticipated need to alter psychotropic medications for the duration of the study * ability of patient to fully participate in the informed consent process exclusion criteria: * unstable or serious medical condition that substantially increases risks of ect or of cognitive impairment * substance use disorders within 1 week of randomization * history of neurological disorder, epilepsy, stroke, brain surgery, metal in the head, history of known structural brain lesion that is deemed to affect cognition or safe ect treatment * vagal nerve stimulator implanted * female patients who are pregnant or plan to be pregnant during the study breast-feeding * implanted devices that make ect unsafe, or a skull defect * significant cognitive impairment (mini-mental state examination (mmse) less than 24) * ect in the past 1 months * benzodiazepine use will be limited to no more than 3 mg per day of lorazepam or its equivalents. antidepressants and antipsychotics will be held constant during the ect course of the study

Keywords: electroconvulsive therapy low pulse amplitude focal electroconvulsive therapy ect depression suicidal ideation
azd8330 first time in man in patients with advanced malignancies

Conditions: Cancer

Summary: the primary purpose of this protocol is to investigate the safety and tolerability of azd8330 (arry-424704) in patients with advanced malignancies


Eligibility criteria:
inclusion criteria: * cancer which is refractory to standard therapies, or no therapies exist; exclusion criteria: * participated in radiotherapy, biological or chemotherapy within 21 days prior to study start; * hasn't participated in investigation drug study within 30 days; * brain metastases/spinal cord compression unless treated and stable, * off steroids/anticonvulsants.

Keywords: advanced malignancies
a study to investigate the safety, tolerability and preliminary efficacy of ngi226 microparticles in patients with achilles tendinopathy

Conditions: Achilles Tendinopathy

Summary: the purpose of this study is to measure local and systemic safety and tolerability as well as improvement of achilles tendon mechanical properties after a single peritendon injection of ngi226 mp in comparison to placebo mp in patients with mid-portion achilles tendinopathy.


Eligibility criteria:
inclusion criteria: * written informed consent must be obtained prior to all study specific screening procedures, as close to the start of the screening period as possible. * presence of clinically (local achilles tendon pain on tendon-loading activities, pain on palpation at the level 2-6 cm proximal to the calcaneal insertion) and ultrasound (local tendon thickening with hypoechogenicities and irregular fibre orientation) or mri diagnosed mid-portion achilles tendinopathy with symptoms present ≥8 weeks but \<12 months at screening. * the achilles tendinopathy must have been refractory to at least 6 weeks of conservative treatment (physiotherapy, nsaids, rice), but participants do not need to be in physiotherapy at the time of study entry. exclusion criteria: * medical condition that would affect safety of peritendon injection (e.g., peripheral vascular disease, use of anticoagulant medication) * history of recurrent, acute, symptomatic infections, including outbreaks of oral or genital herpes (\> 2 symptomatic infections or \>2 courses of anti-infective treatments required in the last 6 months; active systemic infection during last 2 weeks; known active infections (e.g. chronic or active hepatis b or c, hiv) - simple cold excluded * history or evidence of clinically significant cardiac or cardiovascular disease * history of deep vein thrombosis, pulmonary embolism or evidence of primary or secondary hypercoagulable states * history of surgical intervention for the treatment of tendinopathy, history of ankle surgery, ankle arthritis, traumatic, inflammation or deformity of ankle * history of full-thickness tear or complete rupture of the achilles tendon

Keywords: achilles tendon; mid-portion achilles tendinopathy; peritendon injection
solar- frailty screening and multidisciplinary assessment of older adults in the emergency department

Conditions: Frailty

Summary: solar is a randomised control trial exploring the role of comprehensive geriatric assessment (cga) in older adults who screen positive for frailty based on the identification of seniors at risk (isar) tool the the emergency department and acute medical assessment unit of a university teaching hospital.

all patients who are over seventy-five will be screened for frailty using the widely used isar tool. those with a score of 2 or above in the isar will be randomised. the treatment arm will undergo geriatric medicine team-directed cga from admission to emergency department (ed) or acute medical assessment unit (amau) whereby the non-treatment arm will undergo usual patient care. a dedicated multidisciplinary team of a geriatric medicine trainee, physiotherapist, occupational therapist and medical social worker will carry out the assessment, as well as interventions that arise from that assessment. primary outcomes will be time from triage to decision to admit or discharge. secondary outcomes will be subsequent emergency department reattendance, rehospitalisation, functional decline and mortality at 30 days and 180 days. this will be recorded by telephone consultation and electronic records.

Eligibility criteria:
inclusion criteria: * older adults aged 75 years or over * medically stable as deemed by the treating physician * a score of 2 or above on the isar * present with a medical complaint exclusion criteria: * those under the age of 75 years * a score of less than 2 on the isar * acute myocardial infarction, stroke or non-medical problems e.g. surgical or psychiatric issues * patients who are medically unstable * if neither the patient nor carer can communicate in english sufficiently to complete consent or baseline assessment * confirmed or highly suspicious of symptoms for covid 19.

Keywords: comprehensive geriatric assessment emergency department older adults frailty
predictive role of [11c] choline pet/ct on survival in prostate cancer patients with biochemical failure.

Conditions: Prostate Cancer

Summary: several studies have shown that the pet/ct study with choline is of great use in the restaging of patients with prostate cancer who present a recurrence of biochemical disease following primary treatment. despite the large amount of literature in which the diagnostic accuracy of the method is highlighted in the identification of the recurrence of prostatic disease both in the case of local recurrence, lymph node recurrence and metastatic disease, there are to date no studies that evaluate whether pet /ct with choline may predict survival in patients radically treated for prostate cancer. the aim of the study is to evaluate the predictive role of choline pet/ct on the survival of patients with biochemical recovery of the disease during hormonal therapy. this retrospective study will include adult patients affected by prostate cancer with biochemical recurrence of the disease following radical prostatectomy treatment and undergoing hormonal therapy who underwent, between 2004 and 2007, a pet/ct study with choline for the restaging of their disease. the expected result is to establish how pet/ct with choline can predict survival in patients who develop a biochemical recurrence of the disease during hormonal therapy. if this result is confirmed, pet/ct with choline could be even more useful in the follow-up of patients radically treated for prostate cancer to plan the best therapeutic approach.


Eligibility criteria:
inclusion criteria: * patients who have been treated with radical prostatectomy; * patients who present a progressive increase in psa value during hormonal treatment. exclusion criteria: * patients\< 18 years
outpatient floor pedal bike utilization

Conditions: Femur Fracture; Tibia Fracture; Ankle Injuries

Summary: the goals of this clinical trial are: to test the feasibility of identifying patients and getting patients the floor pedal bikes, to test how well floor pedal bikes help patients with lower body injuries heal, and to test methods of patient self-reported logs for home pedal bike use. participants will be given a floor pedal bike at first post-operative appointment where weightbearing restrictions are lifted (weight-bearing as tolerated) along with instructions on utilization. participants will be asked to complete patient reported outcome measure surveys at each follow-up visit.

the goals of this clinical trial are: 1. to test the feasibility of identifying patients and getting patients the floor pedal bikes themselves 2. to test the efficacy of floor pedal bikes in the rehabilitation of patients with lower extremity orthopedic trauma injuries without formal physical therapy or as a supplement to preexisting and/or future physical therapy. we hope that these bikes will either supplement patient's preexisting therapy or allow them to complete therapy at home if they are unable to obtain formal physical therapy and 3. to test various methods of patient self-reported logs for home pedal bike utilization, whether electronic or hard paper copy. participants will be given a floor pedal bike at first post-operative appointment where weightbearing restrictions are lifted (weight-bearing as tolerated) along with instructions on utilization. participants will be asked to complete patient reported outcome measure surveys at each follow-up visit.

Eligibility criteria:
inclusion criteria: * patients \>18 years of age * operative fractures of the femur, tibia and select ankle injuries * under the care of an orthopaedic surgeon * english or spanish competent * 12 month follow up exclusion criteria: * type iiib/c fracture * unable to provide consent/need for an lar * major lower extremity peripheral nerve injury (ex. foot drop, sciatic nerve palsy, etc)

Keywords: floor pedal bike lower extremity rehabilitation